Syndax Pharmaceuticals, Inc.
SNDX
$23.93
$0.431.81%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 794.90% | 266.97% | 717.14% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 794.90% | 266.97% | 984.51% | -- | -- |
| Cost of Revenue | 22.59% | -17.74% | 30.52% | -- | 20.37% |
| Gross Profit | 78.49% | 78.61% | 43.42% | -- | -6.44% |
| SG&A Expenses | 32.48% | 44.40% | 50.73% | 78.23% | 66.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.19% | 1.20% | 38.08% | 30.23% | 33.94% |
| Operating Income | 34.88% | 35.89% | 6.55% | -5.03% | -24.08% |
| Income Before Tax | 27.58% | 27.83% | -5.56% | -17.19% | -30.35% |
| Income Tax Expenses | -33.33% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.77% | 27.83% | -5.56% | -17.19% | -29.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.77% | 27.83% | -5.56% | -17.19% | -29.94% |
| EBIT | 34.88% | 35.89% | 6.55% | -5.03% | -24.08% |
| EBITDA | 34.88% | 35.89% | 6.55% | -5.03% | -24.09% |
| EPS Basic | 28.71% | 28.82% | -4.26% | -15.89% | -9.85% |
| Normalized Basic EPS | 28.51% | 28.81% | -4.25% | -15.89% | -10.18% |
| EPS Diluted | 28.71% | 28.82% | -4.03% | -15.84% | -9.32% |
| Normalized Diluted EPS | 28.51% | 28.81% | -4.25% | -15.89% | -10.18% |
| Average Basic Shares Outstanding | 1.30% | 1.39% | 1.25% | 1.13% | 18.30% |
| Average Diluted Shares Outstanding | 1.30% | 1.39% | 1.25% | 1.13% | 18.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |